Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A flexible technology platform to explore valuable drug targets.

J H Connick1

  • 1Lead Discovery Pharmacology, Organon Laboratories Ltd., Newhouse, Lanarkshire ML1 5SH, UK. j.connick@organon.com

Biochemical Society Transactions
|August 28, 2002
PubMed
Summary

High-throughput screening for drug discovery prioritizes therapeutic areas, influencing speed and data. Future lead discovery will rely more on rich information content than just high throughput.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clozapine-induced dopamine levels in the rat striatum and nucleus accumbens are not affected by muscarinic antagonism.

European journal of pharmacology·1999
Same author

Multiple sigma binding sites in guinea-pig and rat brain membranes: G-protein interactions.

British journal of pharmacology·1992
Same author

The sigma ligand 1,3-di-o-tolylguanidine depresses amino acid-induced excitation non-selectively in rat brain.

European journal of pharmacology·1992
Same author

Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity.

General pharmacology·1992
Same author

Interactions of adenosine and magnesium on neuronal excitability and transmitter sensitivity in the hippocampal slice.

Epilepsy research. Supplement·1992
Same author

Changes in neurotransmitter sensitivity in the mouse neocortical slice following propranolol and theophylline administration.

British journal of pharmacology·1991

Area of Science:

  • Drug discovery and development
  • Pharmacology
  • Biotechnology

Background:

  • High-throughput screening (HTS) platforms are crucial for modern drug discovery.
  • The efficiency of HTS is often dictated by specific therapeutic areas of interest.
  • Adaptability to emerging technologies is essential for maintaining platform relevance.

Purpose of the Study:

  • To analyze the factors governing the speed and information output of HTS platforms.
  • To highlight the importance of technological adaptability in drug discovery.
  • To propose a future direction for HTS, emphasizing information content over sheer speed.

Main Methods:

  • Analysis of current high-throughput screening platform functionalities.
  • Review of technological advancements relevant to drug discovery.

Related Experiment Videos

  • Evaluation of the impact of therapeutic area focus on screening processes.

    • Main Results:

    • HTS platform performance is intrinsically linked to the chosen therapeutic areas.
    • A trend towards prioritizing speed and throughput in recent years has been observed.
    • The study identifies a shift needed in HTS strategy.

    Conclusions:

    • Future drug lead discovery will be significantly advanced by higher information content generated through HTS.
    • Integrating diverse technologies and adapting to new ones is key.
    • A balanced approach, considering both speed and data richness, is optimal for HTS success.